Description du projet
Inhibition de Myc dans le cancer du pancréas
Myc est un oncogène qui joue un rôle essentiel dans la progression du cancer, en particulier dans l’adénocarcinome canalaire pancréatique (PDAC), où il demeure une cible thérapeutique difficile à atteindre. Financé par le Conseil européen de l’innovation, le projet MYCureX entend remédier aux options limitées pour ce cancer hautement létal en ciblant Myc. Le projet initie une avancée avec OMO-103, un inhibiteur de Myc qui a passé avec succès un essai de phase 1 et a démontré une efficacité considérable chez les patients atteints de PDAC. Soutenu par des tests de diagnostic compagnon générés par l’IA, le projet MYCureX entend faire progresser l’inhibiteur jusqu’à un essai de phase 1b, l’associant aux soins standard, affinant les diagnostics, garantissant une fabrication évolutive et élargissant les applications. L’objectif est de consolider le potentiel thérapeutique de l’inhibition de Myc, offrant une solution prometteuse pour le traitement du PDAC.
Objectif
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with very few and often ineffective therapeutic options. Despite recent advances, cancer therapies remain ineffective and/or highly toxic. Our approach is targeting MYC, a function essential to cancer cells that allows them to survive and develop resistance to therapy. In contrast to standard drugs, inhibiting MYC selectively blocks tumor progression without causing important side effects. MYC has been considered undruggable for a long time, and no clinical MYC inhibitor is yet marketed. Peptomyc’s first-in-class drug, OMO-103, is a cell-penetrating mini-protein that derives from Omomyc, the best MYC inhibitor known to date. OMO-103 recently completed a Phase 1 clinical trial that confirmed its safety and clinical activity in all-comers solid tumor patients, causing a 49% tumor shrinkage in a PDAC patient and stabilizing the disease of 8 out of 12 evaluable patients. Moreover, using AI we identified a predictive and a pharmacodynamic circulating biomarker signatures, and generated companion diagnostic for stratification and real-time response monitoring tests for OMO-103. OMO-103 and its companion diagnostic tests offer a promising therapeutic option for a disease in great need and could apply to treat many other cancer indications. The next steps and goals of this MYCureX project consist of conducting a Phase 1b trial in 1st-line PDAC patients, combining OMO-103 with the standard of care, to evaluate its safety and clinical activity; refining the companion diagnostic prototypes and app; securing the scale-up of the innovation by developing a commercial-scale compatible manufacturing process; and expand the applications of OMO-103 and Peptomyc's drug pipeline. By completing MYCureX, Peptomyc will consolidate the therapeutic potential of MYC inhibition in cancer patients, improving their survival and quality of life while establishing itself as a European leader biotech in MYC targeting.
Champ scientifique
Mots‑clés
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Régime de financement
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinateur
08035 BARCELONA
Espagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.